Mystery Of India’s Dismal 4% November Growth Hidden In Diwali Puzzle
This article was originally published in PharmAsia News
As doctors, stockists and even patients take a Diwali break, sales targets for drug companies see an unexpected blip, albeit a temporary one.
You may also be interested in...
Oncology partnership with Swiss major follows late 2020 pact with Merck KGaA. Pfizer divests Phase Ib breast cancer candidate to Celcuity.
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.
In a bold move, little known Indian drug firm Lee Pharma has applied for a compulsory license for saxagliptin in India, contending that AstraZeneca sells the diabetes drug at an exorbitant local price and that it is not being made sufficiently available. Lee also says that the originator has not responded to calls to collaborate.